Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Honor Health Clinical Research Institute
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine (AA NABPLAGEM) is an investigational combination chemotherapy regimen being evaluated by the Medical College of Wisconsin for the treatment of untreated metastatic pancreatic cancer. This regimen integrates high-dose intravenous ascorbic acid (Vitamin C) with a cytotoxic triplet backbone consisting of nanoparticle albumin-bound (nab)-paclitaxel, cisplatin, and gemcitabine. High-dose ascorbic acid acts as a pro-oxidant, generating hydrogen peroxide in the extracellular space that selectively induces oxidative stress and DNA damage in cancer cells while sparing normal tissue. Nab-paclitaxel is a microtubule-stabilizing agent that inhibits mitosis; gemcitabine is a nucleoside analog that inhibits DNA synthesis via ribonucleotide reductase inhibition; and cisplatin is a platinum-based alkylating agent that forms DNA cross-links. This multi-targeted approach aims to enhance the efficacy of standard-of-care chemotherapy in pancreatic ductal adenocarcinoma by leveraging synergistic mechanisms of DNA damage and metabolic stress.
- Other names
- AA + nab-paclitaxel + cisplatin + gemcitabinehigh dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine
02
Targets
RNR (Ribonucleotide reductase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine.